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Summary.-S.c. cellular transplants of MS tumours have a high incidence ofrejection
in adult BALB/c mice, which can then be used as syngeneic regressors. When these
tumours were inoculated within a glass cylinder which had been implanted s.c. in
BALB/c mice 2 days earlier, 5100 of the animals died with progressively growing
tumours, compared with 2% in animals which had received the same inoculum
directly s.c. This experimental model demonstrates tumour enhancement in a syn-
geneic system, and duplicates what has been previously reported in two different allo-
geneic tumour-host combinations, where it was demonstrated that immunological
enhancement was operating, since the addition of either progressor serum or soluble
tumour antigen significantly increased tumour incidence. For the purpose of investi-
gating whether the glass cylinder model could also modify the immune response of
the host to a second tumour challenge, a leukaemia virus known to crossreact with
MS was used. Regressors were challenged i.p. with a lethal dose of a leukaemia
virus, PLLV. Regressors bearing a glass cylinder showed a 22% survival rate which
was significantly lower than that of the s.c. inoculated regressors (71%). This
decrease in cross-immunity suggests that the artificially constructed privileged site
created by the glass cylinder, by conditioning for tumour enhancement, also
decreases immunological memory.
AN in vivo experimental model has been
described in which AKR lymphoma allo-
grafts were conditioned to grow by inocu-
lating them within a glass cylinder
implanted s.c. in BALB/c mice. Tumour
growth was attributed to immunological
enhancement since the serum of animals
bearing actively growing tumours pos-
sessed factors capable ofincreasing tumour
incidence (Saai et al., 1972; 1973). It has
also been shown in our laboratory that
Moloney sarcoma cross-immunizes against
a leukaeinia virus, PLLV (Precerutti-
Law leukaemia virus) (Basombrio et al.,
1977).
The object, of this paper is two-fold:
firstly, to demonstrate that by using the
glass cylinder model it is possible to
obtain tumour enhancement in a syngeneic
system consisting of Moloney sarcoma
(MS) cellular transplants in BALB/c
mice, and secondly, to show that this
immunologically privileged site condi-
tioning for tumour enhancement (Pas-
qualini and Colmerauer, 1976a) also leads
to a decrease in the cross-immunity
observed between MS and PLLV.
MATERIALS AND METHODS
Glass cylinders made of neutral glass
tubing, 1 cm in diameter and 1-5 cm in
length, were implanted under the skin of
2-4-month-old BALB/c mice of both sexes.
* Research Fellow, CONICET (Consejo Nacional de Investigaciones Cientificas y T6cnicas).
t Member of Research Career, CONICET.
Address for reprints: Dra C. Dosne Pasqualini, Academia Nacional de Medicina, Las Heras 3092, 1425
Buenos Aires, Argentina.A. M. S. MAYER, M. A. BASOMBRIO AND C. D. PASQUALINI
Two days later, a fragment of Moloney
sarcoma (MS) was loaded in a 15-gauge
trocar and discharged into the glass cylinder
with 0-2 ml of physiological saline. Mice
without cylinders received the same tumour
challenge by s.c. route. MS was obtained
from a rapidly growing tumour in 10-day-old
BALB/c mice which had been inoculated at
birth with MSV (Lot SVR-P166, obtained
from Dr K. E. Hellstrom, University of
Washington, Seattle, U.S.A.). Four different
experiments were carried out.
Regressors (mice which had rejected MS)
were challenged with PLLV (Precerutti and
Law, 1963): this leukaemia was introduced
in our laboratory by Dr A. Precerutti 8
years ago and the virus has been maintained
since then in BALB/c mice. It is characterized
by the early development of a markedly
enlarged spleen (10 x normal). All animals
with splenomegaly die of lymphoblastic
leukaemia (Correa et al., 1976). Virus prepara-
tions were obtained from leukaemic spleens
17-28 days after inoculation: a 10% homo-
genate in physiological saline was clarified
twice at 1000 and 8000 g for 15 min in a
refrigerated centrifuge. Each animal received
0-2 ml i.p. of a 10-3 dilution, corresponding
to a 5-1 x 103 LD50(60)/ml. Titre was
calculated by the Reed-Muench method,
estimating lethal dose at Day 60, and
expressed as LD50(60)/ml.
RESULTS
As can be seen in Table I, s.c. implan-
tation of MS led to tumour growth and
regression in nearly all animals within 23
days, only 1/46 dying, 2%0 (Group 1).
TABLE I.-Increased Lethality of Moloney
Sarcoma (MS) after Inoculation in a
Glass Cylinder (GC) Implanted s.c. in
BALB/c Mice (Data from 4 Different
Experiments)
Route of
MS Lethal
Group transplant tumours*/mouse % Pt
1 s.c. l1/46 2
<0-001
2 in GC: 24/47 51
* With an average time to death of 45 dlays in all
groups.
t Calculated by x2 test.
t Glass cylinder implanted s.c., 2 days before
tumour inoculation within it.
In contrast, s.c. implantation of a glass
cylinder, followed 2 days later by the
inoculation of MS within it, led to the
growth of tumours in all animals, but in
this case 24/47 (510%) died (Group 2)
that is, a statistically significant increase
in lethal tumour incidence was observed
after inoculation within the glass cylinder
(P < 0l001).
Macroscopically, the circumscribed local
growth of MS after s.c. transplantation
contrasted with the expansive tumour
growth involving the dorsal muscular
panniculum after a transplant within the
glass cylinder. MS did not grow either
inside or enclosing the foreign body, as
in other tumour systems (Saal et al., 1972;
Pasqualini and Colmerauer, 1976b), but
grew extensively underneath it, even in
animals in which the tumour eventually
regressed. MS regressors from both groups
were challenged with PLLV and the
results are summarized in Table II.
TABLE II.-Cross-iimmunization between
Moloney Sarcoma (MS) and a Leukaemia
Virus, PLLV. Decreased Immunity in
Regressors Bearing a Glass Cylinder (GC)
Challenge
Route of with PLLV*
immuni- survivors/
Group zation mouset
Control
1 s.c.
%/1
0/18 0
17/24 71
Pt
<0-001
2 in GC§ 4/19 22
* 0-2 ml of a 10-3 dilution of a standard PLLV
preparation.
t With an average time to death of 40 days in all
groups.
I Calculated by x2 test.
§ S.c. implanted glass cylinder.
5.1 X 103 LD50/ml was 1000% lethal
in the controls. Regressors in Group 2
inoculated with PLLV showed a 710 sur-
vival, compared with 22% for those which
had received MS in the glass cylinder
(Group 2). These results were statistically
significant. There was no difference in
leukaemia latency, animals in all groups
dying at an average of 35 days. The
experiments were terminated after 90
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days and no sarcoma or leukaemia
relapses were observed.
DISCUSSION
Two main findings resulted from this
study. First, the demonstration that the
growth of a syngeneic tumour, MS in
BALB/c mice, can be enhanced when the
tumour is inoculated in an artificially
constructed privileged site created by the
s.c. implantation of a glass cylinder.
Second, that animals which reject such
enhanced MS tumours show less cross-
immunity against the viral leukaemia
PLLV than regressors after a subcuta-
neous MS transplant.
The studies which originally led to the
elaboration ofthe concept ofenhancement
were carried out with allogeneic murine
tumours (Kaliss and Bryant, 1958). In
our laboratory, using the glass cylinder
model, it was demonstrated that an AKR
lymphoma could be made to grow in
BALB/c mice. That this increase in
tumour growth could be ascribed to
immunological enhancement, as originally
described by Kaliss (1969), was demon-
strated bothpassively andactively,repeat-
ing Kaliss' original experiments: (1) The
addition of progressor serum further
increased tumour incidence (Saal et al.,
1972, 1973); (2) Pretreatment of the host
with specific tumour extracts (but not
spleen extracts) led to a state of maximal
enhancement, most of the animals dying
with huge tumours (Colmerauer and
Pasqualini, 1975; Pasqualini and Col-
merauer, 1976a). Similar results were
obtained in a second tumour-host com-
bination, consisting of Sarcoma 180 in
Swiss mice (Pasqualini and Colmerauer,
1976b, 1976c).
It has often been stated that immuno-
logical enhancement could not be demon-
strated with syngeneic tumours (Currie,
1976). In this paper, however, enhanced
tumour growth is observed in a syngeneic
system, which by analogy with the
allogeneic tumour-host models can be
ascribed to immunological enhancement.
This is made possible by the use of a
tumour, MS, which when inoculated s.c.
grows and regresses in most adult BALB/c,
giving a leeway for enhancement not
available in syngeneic transplants which
kill all animals. The mechanism by which
tumour challenge within the glass cylinder
leads to enhancement is not clear. It has
been tentatively related to: (1) a 6-day
delay in seeding of the tumour cells
inoculated in a liquid environment so that
the host is somehow "pretreated" with
soluble tumour antigen (Filippa and
Pasqualini, 1975); and/or (2) marked
macrophage adherence on both the inner
and outer surfaces of the glass cylinder,
leading to an alteration in antigen proces-
sing (Pasqualini (1976)).
Cross-immunization between MS and
histocompatible FMR leukaemia cells was
described by Fefer, McCoy and Glynn
(1967). In our laboratory, MS proved to
be a good immunogen against the develop-
ment of viral leukaemias, including the
Gross + PLLV (Basombrlo et al., 1977).
This cross-immunization was confirmed
herein with a high survival rate (710%) in
the MS regressors after s.c. transplan-
tation. However, animals bearing a glass
cylinder into whichMShadbeenimplanted
and which had rejected it, proved to be
much less immunized (22%0). It can be
postulated, therefore, that the glass
cylinder, as a privileged site conditioning
tumour enhancement, leads to a decrease
in immunological memory for rejection.
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